Levstek Tina, Vujkovac Bojan, Cokan Vujkovac Andreja, Trebušak Podkrajšek Katarina
Laboratory for Translational Medical Biochemistry, Institute of Biochemistry and Molecular Genetics, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Clinical Institute for Special Laboratory Diagnostics, University Children's Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Front Med (Lausanne). 2023 Mar 23;10:1143905. doi: 10.3389/fmed.2023.1143905. eCollection 2023.
Early initiation is essential for successful treatment of Fabry disease, but sensitive and noninvasive biomarkers of Fabry nephropathy are lacking. Urinary extracellular vesicles (uEVs) represent a promising source of biomarkers of kidney involvement. Among them, microRNAs (miRNAs) are important post-transcriptional regulators of gene expression that contribute to the development and progression of various kidney diseases. We aimed to identify uEV-derived miRNAs involved in the development and/or progression of Fabry nephropathy.
Patients with genetically confirmed Fabry disease and matched control subjects were included. EVs were isolated from the second morning urine by size exclusion chromatography, from which miRNAs were extracted. miRNA urine exosome PCR panels were used to characterize the miRNA signature in a discovery cohort. Individual qPCRs were performed on a validation cohort that included chronological samples. We identified the target genes of dysregulated miRNAs and searched for potential hub genes. Enrichment analyses were performed to identify their potential function.
The expression of miR-21-5p and miR-222-3p was significantly higher in patients with stable renal function and those with progressive nephropathy compared with the corresponding controls. In addition, the expression of miR-30a-5p, miR-10b-5p, and miR-204-5p was significantly lower in patients with progressive nephropathy, however, in the chronological samples, this was only confirmed for miR-204-5p. Some of the identified hub genes controlled by the dysregulated miRNAs have been associated with kidney impairment in other kidney diseases.
The miRNA cargo in uEVs changes with the development and progression of Fabry nephropathy and, therefore, represents a potential biomarker that may provide a new option to prevent or attenuate the progression of nephropathy. Furthermore, dysregulated miRNAs were shown to be potentially associated with pathophysiological pathways in the kidney.
早期开始治疗对于法布里病的成功治疗至关重要,但目前缺乏法布里肾病敏感且无创的生物标志物。尿细胞外囊泡(uEVs)是肾脏受累生物标志物的一个有前景的来源。其中,微小RNA(miRNAs)是基因表达的重要转录后调节因子,参与多种肾脏疾病的发生和发展。我们旨在鉴定参与法布里肾病发生和/或发展的uEV衍生miRNAs。
纳入基因确诊的法布里病患者及匹配的对照受试者。通过尺寸排阻色谱法从晨尿中分离出细胞外囊泡,从中提取miRNAs。使用miRNA尿外泌体PCR检测板对发现队列中的miRNA特征进行表征。对包括时间序列样本的验证队列进行个体定量PCR。我们鉴定了失调miRNAs的靶基因,并寻找潜在的枢纽基因。进行富集分析以确定其潜在功能。
与相应对照组相比,肾功能稳定患者和进行性肾病患者中miR-21-5p和miR-222-3p的表达显著更高。此外,进行性肾病患者中miR-30a-5p、miR-10b-5p和miR-204-5p的表达显著更低,然而,在时间序列样本中,仅miR-204-5p得到证实。一些由失调miRNAs控制的已鉴定枢纽基因与其他肾脏疾病中的肾功能损害有关。
uEVs中的miRNA货物随法布里肾病的发生和发展而变化,因此代表一种潜在的生物标志物,可能为预防或减轻肾病进展提供新的选择。此外,失调的miRNAs被证明可能与肾脏的病理生理途径相关。